NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $175,729 | -19.8% | 2,922 | -2.2% | 0.01% | -28.6% |
| Q4 2022 | $219,096 | -3.5% | 2,987 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $227,000 | +8.6% | 2,987 | -0.7% | 0.01% | +14.3% |
| Q2 2022 | $209,000 | -20.2% | 3,008 | -5.0% | 0.01% | -12.5% |
| Q1 2022 | $262,000 | -18.4% | 3,167 | -25.9% | 0.01% | -11.1% |
| Q4 2021 | $321,000 | -61.5% | 4,275 | -40.5% | 0.01% | -66.7% |
| Q3 2021 | $834,000 | -46.8% | 7,183 | +1.6% | 0.03% | -44.9% |
| Q2 2021 | $1,569,000 | +41.4% | 7,073 | -15.8% | 0.05% | +19.5% |
| Q1 2021 | $1,110,000 | -43.6% | 8,396 | -26.2% | 0.04% | -48.1% |
| Q4 2020 | $1,968,000 | +1526.4% | 11,372 | +953.0% | 0.08% | +1216.7% |
| Q3 2020 | $121,000 | +98.4% | 1,080 | +19.3% | 0.01% | +50.0% |
| Q1 2020 | $61,000 | +144.0% | 905 | +201.7% | 0.00% | +300.0% |
| Q4 2019 | $25,000 | +2400.0% | 300 | +1053.8% | 0.00% | – |
| Q4 2018 | $1,000 | – | 26 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |